Earth Science Tech, Inc. splits its revenue into 2 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Jun 30, 2026 was Sale Of Pharmaceutical Products And Medical Consultations at $9.0 million, 100% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q1 FY2027
Jun 30, 2026
|
Q4 FY2026
Mar 31, 2026
|
Q3 FY2026
Dec 31, 2025
|
Q2 FY2026
Sep 30, 2025
|
Q1 FY2025
Jun 30, 2025
|
Q4 FY2025
Mar 31, 2025
|
Q3 FY2025
Dec 31, 2024
|
Q2 FY2025
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
|
9
|
9
|
8
|
9
|
9
|
9
|
7
|
9
|
| Sale Of Pharmaceutical Products And Medical Consultations |
—
|
9
share 99.7%
|
—
|
—
|
—
|
9
share 99.9%
|
—
|
—
|
—
|
| Other Revenue |
—
|
0
share 0.3%
|
—
|
—
|
—
|
0
share 0.1%
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ETST (OTC)
- Fiscal year ends
- March 31
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1538495
- Former names
- Ultimate Novelty Sports Inc. (until Apr 17, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.